A patient with Graves disease who is pregnant asks about medication management; what should the nurse practitioner tell her?

A patient with Graves disease who is pregnant asks about medication management; what should the nurse practitioner tell her?

• A. Change to propylthiouracil from now until the second trimester.
• B. Continue methimazole throughout pregnancy.
• C. Stop all antithyroid medications during pregnancy.
• D. Use iodine-131 therapy during pregnancy.

Answer: (A)

When managing Graves disease in pregnancy, the goal is to control maternal thyrotoxicosis while minimizing fetal risk, and this requires trimester-specific choices. Methimazole poses a teratogenic risk if used in the first trimester, so the preferred approach is to use propylthiouracil early in pregnancy to protect the developing fetus. Propylthiouracil is then typically switched to methimazole in the second trimester to reduce the risk of liver toxicity associated with propylthiouracil. Therefore, advising to change to propylthiouracil now and continue it through the second trimester aligns with evidence-based practice, balancing fetal safety with effective maternal treatment. Radioactive iodine therapy is contraindicated in pregnancy, and stopping all antithyroid meds would risk maternal hyperthyroidism, while continuing methimazole throughout pregnancy increases first-trimester fetal risk.

When managing Graves disease in pregnancy, the goal is to control maternal thyrotoxicosis while minimizing fetal risk, and this requires trimester-specific choices. Methimazole poses a teratogenic risk if used in the first trimester, so the preferred approach is to use propylthiouracil early in pregnancy to protect the developing fetus. Propylthiouracil is then typically switched to methimazole in the second trimester to reduce the risk of liver toxicity associated with propylthiouracil. Therefore, advising to change to propylthiouracil now and continue it through the second trimester aligns with evidence-based practice, balancing fetal safety with effective maternal treatment. Radioactive iodine therapy is contraindicated in pregnancy, and stopping all antithyroid meds would risk maternal hyperthyroidism, while continuing methimazole throughout pregnancy increases first-trimester fetal risk.